View ValuationBluestar Adisseo 将来の成長Future 基準チェック /26Bluestar Adisseo利益と収益がそれぞれ年間24.9%と6.6%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に9.7% 22.4%なると予測されています。主要情報24.9%収益成長率22.42%EPS成長率Chemicals 収益成長28.6%収益成長率6.6%将来の株主資本利益率9.66%アナリストカバレッジLow最終更新日01 Aug 2026今後の成長に関する最新情報Major Estimate Revision • May 06Consensus revenue estimates increase by 20%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from CN¥18.5b to CN¥22.1b. EPS estimate increased from CN¥0.45 to CN¥1.09 per share. Net income forecast to grow 227% next year vs 57% growth forecast for Chemicals industry in China. Consensus price target up from CN¥12.60 to CN¥17.35. Share price fell 10% to CN¥12.80 over the past week.Price Target Changed • Mar 06Price target increased by 8.0% to CN¥11.45Up from CN¥10.60, the current price target is an average from 2 analysts. New target price is 15% below last closing price of CN¥13.50. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.49 for next year compared to CN¥0.45 last year.Major Estimate Revision • Jun 07Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥16.6b to CN¥16.1b. EPS estimate also fell from CN¥0.61 per share to CN¥0.48 per share. Net income forecast to shrink 1.4% next year vs 43% growth forecast for Chemicals industry in China . Consensus price target of CN¥11.45 unchanged from last update. Share price was steady at CN¥9.61 over the past week.Major Estimate Revision • Mar 01Consensus EPS estimates increase by 16%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥16.4b to CN¥15.8b. EPS estimate rose from CN¥0.529 to CN¥0.614. Net income forecast to grow 42% next year vs 52% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥11.61. Share price fell 6.0% to CN¥10.34 over the past week.Major Estimate Revision • Nov 22Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥15.4b to CN¥15.2b. EPS estimate also fell from CN¥0.473 per share to CN¥0.411 per share. Net income forecast to grow 14% next year vs 53% growth forecast for Chemicals industry in China. Consensus price target of CN¥11.43 unchanged from last update. Share price fell 3.2% to CN¥10.78 over the past week.Price Target Changed • Aug 31Price target increased by 12% to CN¥11.23Up from CN¥10.01, the current price target is an average from 3 analysts. New target price is 9.9% above last closing price of CN¥10.22. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.45 for next year compared to CN¥0.019 last year.すべての更新を表示Recent updatesお知らせ • Jun 30Bluestar Adisseo Company to Report First Half, 2026 Results on Aug 31, 2026Bluestar Adisseo Company announced that they will report first half, 2026 results on Aug 31, 2026Valuation Update With 7 Day Price Move • Jun 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥7.95, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 3.3% over the past three years.Major Estimate Revision • May 06Consensus revenue estimates increase by 20%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from CN¥18.5b to CN¥22.1b. EPS estimate increased from CN¥0.45 to CN¥1.09 per share. Net income forecast to grow 227% next year vs 57% growth forecast for Chemicals industry in China. Consensus price target up from CN¥12.60 to CN¥17.35. Share price fell 10% to CN¥12.80 over the past week.Reported Earnings • May 01First quarter 2026 earnings released: EPS: CN¥0.10 (vs CN¥0.17 in 1Q 2025)First quarter 2026 results: EPS: CN¥0.10 (down from CN¥0.17 in 1Q 2025). Revenue: CN¥4.40b (up 2.4% from 1Q 2025). Net income: CN¥305.5m (down 34% from 1Q 2025). Profit margin: 6.9% (down from 11% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.お知らせ • Apr 30Bluestar Adisseo Company, Annual General Meeting, May 22, 2026Bluestar Adisseo Company, Annual General Meeting, May 22, 2026, at 14:00 China Standard Time. Location: No. 9, Beitucheng West Road, Chaoyang District, Beijing ChinaNew Risk • Apr 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.3% average weekly change).お知らせ • Mar 30Bluestar Adisseo Company to Report Q1, 2026 Results on Apr 30, 2026Bluestar Adisseo Company announced that they will report Q1, 2026 results on Apr 30, 2026Reported Earnings • Mar 10Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: CN¥0.43 (down from CN¥0.45 in FY 2024). Revenue: CN¥17.2b (up 11% from FY 2024). Net income: CN¥1.15b (down 4.1% from FY 2024). Profit margin: 6.7% (down from 7.8% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 4.0% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.Price Target Changed • Mar 06Price target increased by 8.0% to CN¥11.45Up from CN¥10.60, the current price target is an average from 2 analysts. New target price is 15% below last closing price of CN¥13.50. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.49 for next year compared to CN¥0.45 last year.Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥11.66, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 28x in the Chemicals industry in China. Total returns to shareholders of 35% over the past three years.Upcoming Dividend • Feb 20Upcoming dividend of CN¥0.051 per shareEligible shareholders must have bought the stock before 27 February 2026. Payment date: 27 February 2026. Payout ratio is a comfortable 38% but the company is paying out more than the cash it is generating. Trailing yield: 1.7%. Lower than top quartile of Chinese dividend payers (1.8%). Higher than average of industry peers (1.2%).お知らせ • Dec 26Bluestar Adisseo Company to Report Fiscal Year 2025 Results on Mar 07, 2026Bluestar Adisseo Company announced that they will report fiscal year 2025 results on Mar 07, 2026Reported Earnings • Oct 31Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: EPS: CN¥0.094 (down from CN¥0.14 in 3Q 2024). Revenue: CN¥4.42b (up 7.4% from 3Q 2024). Net income: CN¥250.2m (down 37% from 3Q 2024). Profit margin: 5.7% (down from 9.6% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 45%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Sep 30Bluestar Adisseo Company to Report Q3, 2025 Results on Oct 31, 2025Bluestar Adisseo Company announced that they will report Q3, 2025 results on Oct 31, 2025Reported Earnings • Sep 04Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: EPS: CN¥0.11 (down from CN¥0.13 in 2Q 2024). Revenue: CN¥4.21b (up 12% from 2Q 2024). Net income: CN¥275.4m (down 17% from 2Q 2024). Profit margin: 6.5% (down from 8.8% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • Jun 30Bluestar Adisseo Company to Report First Half, 2025 Results on Aug 30, 2025Bluestar Adisseo Company announced that they will report first half, 2025 results on Aug 30, 2025Major Estimate Revision • Jun 07Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥16.6b to CN¥16.1b. EPS estimate also fell from CN¥0.61 per share to CN¥0.48 per share. Net income forecast to shrink 1.4% next year vs 43% growth forecast for Chemicals industry in China . Consensus price target of CN¥11.45 unchanged from last update. Share price was steady at CN¥9.61 over the past week.Reported Earnings • May 01First quarter 2025 earnings released: EPS: CN¥0.17 (vs CN¥0.10 in 1Q 2024)First quarter 2025 results: EPS: CN¥0.17 (up from CN¥0.10 in 1Q 2024). Revenue: CN¥4.30b (up 23% from 1Q 2024). Net income: CN¥464.8m (up 68% from 1Q 2024). Profit margin: 11% (up from 7.9% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.お知らせ • Mar 28Bluestar Adisseo Company to Report Q1, 2025 Results on Apr 29, 2025Bluestar Adisseo Company announced that they will report Q1, 2025 results on Apr 29, 2025Major Estimate Revision • Mar 01Consensus EPS estimates increase by 16%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥16.4b to CN¥15.8b. EPS estimate rose from CN¥0.529 to CN¥0.614. Net income forecast to grow 42% next year vs 52% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥11.61. Share price fell 6.0% to CN¥10.34 over the past week.お知らせ • Feb 28Bluestar Adisseo Company, Annual General Meeting, Mar 24, 2025Bluestar Adisseo Company, Annual General Meeting, Mar 24, 2025, at 14:00 China Standard Time. Location: No. 9, Beitucheng West Road, Chaoyang District, Beijing China分析記事 • Feb 06We Think Bluestar Adisseo (SHSE:600299) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Jan 12Estimating The Fair Value Of Bluestar Adisseo Company (SHSE:600299)Key Insights Bluestar Adisseo's estimated fair value is CN¥12.50 based on 2 Stage Free Cash Flow to Equity Bluestar...お知らせ • Dec 27Bluestar Adisseo Company to Report Fiscal Year 2024 Results on Feb 28, 2025Bluestar Adisseo Company announced that they will report fiscal year 2024 results on Feb 28, 2025分析記事 • Dec 25Returns At Bluestar Adisseo (SHSE:600299) Appear To Be Weighed DownIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...分析記事 • Dec 06Investor Optimism Abounds Bluestar Adisseo Company (SHSE:600299) But Growth Is LackingWith a median price-to-sales (or "P/S") ratio of close to 2.4x in the Chemicals industry in China, you could be...Major Estimate Revision • Nov 22Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥15.4b to CN¥15.2b. EPS estimate also fell from CN¥0.473 per share to CN¥0.411 per share. Net income forecast to grow 14% next year vs 53% growth forecast for Chemicals industry in China. Consensus price target of CN¥11.43 unchanged from last update. Share price fell 3.2% to CN¥10.78 over the past week.Reported Earnings • Oct 30Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.014 loss in 3Q 2023). Revenue: CN¥4.11b (up 25% from 3Q 2023). Net income: CN¥395.7m (up CN¥463.5m from 3Q 2023). Profit margin: 9.6% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) also surpassed analyst estimates by 4.0%. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.分析記事 • Oct 11We Think Bluestar Adisseo (SHSE:600299) Can Manage Its Debt With EaseDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...お知らせ • Sep 30Bluestar Adisseo Company to Report Q3, 2024 Results on Oct 30, 2024Bluestar Adisseo Company announced that they will report Q3, 2024 results on Oct 30, 2024Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥11.29, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 1.0% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.84 per share.分析記事 • Sep 23Bluestar Adisseo (SHSE:600299) Is Finding It Tricky To Allocate Its CapitalWhat financial metrics can indicate to us that a company is maturing or even in decline? Businesses in decline often...Reported Earnings • Sep 04Second quarter 2024 earnings: EPS in line with expectations, revenues disappointSecond quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.011 in 2Q 2023). Revenue: CN¥3.77b (up 19% from 2Q 2023). Net income: CN¥330.7m (up CN¥298.8m from 2Q 2023). Profit margin: 8.8% (up from 1.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.分析記事 • Sep 04Getting In Cheap On Bluestar Adisseo Company (SHSE:600299) Is UnlikelyThere wouldn't be many who think Bluestar Adisseo Company's ( SHSE:600299 ) price-to-sales (or "P/S") ratio of 2x is...Price Target Changed • Aug 31Price target increased by 12% to CN¥11.23Up from CN¥10.01, the current price target is an average from 3 analysts. New target price is 9.9% above last closing price of CN¥10.22. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.45 for next year compared to CN¥0.019 last year.お知らせ • Jun 28Bluestar Adisseo Company to Report First Half, 2024 Results on Aug 30, 2024Bluestar Adisseo Company announced that they will report first half, 2024 results on Aug 30, 2024分析記事 • Jun 21Are Investors Undervaluing Bluestar Adisseo Company (SHSE:600299) By 32%?Key Insights Bluestar Adisseo's estimated fair value is CN¥14.20 based on 2 Stage Free Cash Flow to Equity Bluestar...お知らせ • Jun 08Bluestar Adisseo Company, Annual General Meeting, Jun 26, 2024Bluestar Adisseo Company, Annual General Meeting, Jun 26, 2024, at 14:00 China Standard Time. Location: No. 9, Beitucheng West Road, Chaoyang District, Beijing ChinaReported Earnings • Apr 27First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: EPS: CN¥0.10 (up from CN¥0.001 in 1Q 2023). Revenue: CN¥3.50b (up 11% from 1Q 2023). Net income: CN¥276.9m (up CN¥275.4m from 1Q 2023). Profit margin: 7.9% (up from 0% in 1Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Apr 27Bluestar Adisseo Company announced that it expects to receive CNY 3 billion in fundingBluestar Adisseo Company announced a private placement of not more than 804,570,381 shares for the gross proceeds of not more than CNY 3,000,000,000 on April 25, 2024. The company shall issue shares at a price not less than 80% of the average price in the 20 trading days before the pricing reference date. The transaction will include participation from no more than 35 investors. The transaction has been approved by the shareholders of the company in the 18th meeting of the 8th board of directors and the 12th meeting of the 8th board of supervisors. The transaction is subject to to review and approval by the listed company’s general meeting of shareholders; by the Shanghai Stock Exchange and approval by the China Securities Regulatory Commission for registration.分析記事 • Apr 25Bluestar Adisseo's (SHSE:600299) Returns On Capital Not Reflecting Well On The BusinessWhen we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...分析記事 • Apr 04There May Be Some Bright Spots In Bluestar Adisseo's (SHSE:600299) EarningsBluestar Adisseo Company's ( SHSE:600299 ) recent soft profit numbers didn't appear to worry shareholders, as the stock...Reported Earnings • Mar 31Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: CN¥0.02 (down from CN¥0.47 in FY 2022). Revenue: CN¥13.2b (down 9.3% from FY 2022). Net income: CN¥52.2m (down 96% from FY 2022). Profit margin: 0.4% (down from 8.6% in FY 2022). Revenue missed analyst estimates by 7.8%. Earnings per share (EPS) also missed analyst estimates by 68%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.お知らせ • Mar 29Bluestar Adisseo Company to Report Q1, 2024 Results on Apr 26, 2024Bluestar Adisseo Company announced that they will report Q1, 2024 results on Apr 26, 2024分析記事 • Mar 27Is Bluestar Adisseo (SHSE:600299) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Major Estimate Revision • Mar 08Consensus EPS estimates increase by 21%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from CN¥0.069 to CN¥0.084. Revenue forecast steady at CN¥14.3b. Net income forecast to grow 959% next year vs 59% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥9.88. Share price fell 2.1% to CN¥8.46 over the past week.分析記事 • Mar 06Optimistic Investors Push Bluestar Adisseo Company (SHSE:600299) Shares Up 25% But Growth Is LackingBluestar Adisseo Company ( SHSE:600299 ) shareholders would be excited to see that the share price has had a great...分析記事 • Feb 28Is There An Opportunity With Bluestar Adisseo Company's (SHSE:600299) 32% Undervaluation?Key Insights Using the 2 Stage Free Cash Flow to Equity, Bluestar Adisseo fair value estimate is CN¥12.56 Current share...お知らせ • Dec 29Bluestar Adisseo Company to Report Fiscal Year 2023 Results on Mar 29, 2024Bluestar Adisseo Company announced that they will report fiscal year 2023 results on Mar 29, 2024Major Estimate Revision • Nov 14Consensus EPS estimates increase by 10%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CN¥15.0b to CN¥14.7b. EPS estimate rose from CN¥0.134 to CN¥0.147. Net income forecast to grow 1,037% next year vs 70% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥9.81. Share price was steady at CN¥7.76 over the past week.Reported Earnings • Nov 01Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: CN¥0.014 loss per share (down from CN¥0.10 profit in 3Q 2022). Revenue: CN¥3.29b (down 8.8% from 3Q 2022). Net loss: CN¥67.8m (down 125% from profit in 3Q 2022). Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.New Risk • Aug 06New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (111% payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin).Reported Earnings • Aug 05Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: CN¥0.008 (down from CN¥0.16 in 2Q 2022). Revenue: CN¥3.18b (down 15% from 2Q 2022). Net income: CN¥31.9m (down 93% from 2Q 2022). Profit margin: 1.0% (down from 12% in 2Q 2022). Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 94%. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 28Bluestar Adisseo Company to Report First Half, 2023 Results on Aug 05, 2023Bluestar Adisseo Company announced that they will report first half, 2023 results on Aug 05, 2023Major Estimate Revision • Jun 01Consensus revenue estimates decrease by 17%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CN¥15.3b to CN¥12.8b. EPS estimate unchanged from CN¥0.58 per share at last update. Chemicals industry in China expected to see average net income growth of 47% next year. Consensus price target down from CN¥11.84 to CN¥10.42. Share price was steady at CN¥7.96 over the past week.Reported Earnings • Apr 28First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.16 in 1Q 2022). Revenue: CN¥3.15b (down 8.8% from 1Q 2022). Net income: CN¥1.49m (down 100% from 1Q 2022). Profit margin: 0% (down from 12% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Price Target Changed • Apr 06Price target decreased by 7.6% to CN¥11.84Down from CN¥12.81, the current price target is an average from 4 analysts. New target price is 27% above last closing price of CN¥9.29. Stock is down 4.0% over the past year. The company is forecast to post earnings per share of CN¥0.55 for next year compared to CN¥0.55 last year.Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Caroline Sainte-Marie was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Major Estimate Revision • Nov 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from CN¥0.61 to CN¥0.54. Revenue forecast unchanged from CN¥14.8b at last update. Net income forecast to grow 43% next year vs 44% growth forecast for Chemicals industry in China. Consensus price target of CN¥12.76 unchanged from last update. Share price fell 8.9% to CN¥8.73 over the past week.Reported Earnings • Oct 28Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: EPS: CN¥0.10 (down from CN¥0.17 in 3Q 2021). Revenue: CN¥3.60b (up 7.2% from 3Q 2021). Net income: CN¥274.2m (down 37% from 3Q 2021). Profit margin: 7.6% (down from 13% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.0%. Earnings per share (EPS) missed analyst estimates by 28%. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥10.76, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥5.70 per share.Price Target Changed • Aug 18Price target decreased to CN¥12.76Down from CN¥14.22, the current price target is an average from 5 analysts. New target price is 35% above last closing price of CN¥9.46. Stock is down 13% over the past year. The company is forecast to post earnings per share of CN¥0.57 for next year compared to CN¥0.55 last year.Major Estimate Revision • Aug 04Consensus EPS estimates fall by 22%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥15.3b to CN¥14.2b. EPS estimate also fell from CN¥0.73 per share to CN¥0.57 per share. Net income forecast to grow 33% next year vs 41% growth forecast for Chemicals industry in China. Consensus price target down from CN¥14.53 to CN¥14.13. Share price fell 5.6% to CN¥9.18 over the past week.Reported Earnings • Jul 30Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.16 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.16 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥3.74b (up 25% from 2Q 2021). Net income: CN¥442.1m (down 1.6% from 2Q 2021). Profit margin: 12% (down from 15% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 6.5%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Price Target Changed • Jun 24Price target decreased to CN¥13.40Down from CN¥15.11, the current price target is an average from 3 analysts. New target price is 38% above last closing price of CN¥9.70. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥0.72 for next year compared to CN¥0.55 last year.お知らせ • May 07Bluestar Adisseo Company, Annual General Meeting, May 16, 2022Bluestar Adisseo Company, Annual General Meeting, May 16, 2022, at 14:30 China Standard Time. Location: Bluestar Building, 9 Beituchengxi Road, Chaoyang District, Beijing Bejing China Agenda: To consider 2022 annual report and executive summary; to consider 2022 annual final accounts; to consider Board's report for FY 2022; to consider Board of Supervisors' report for FY 2022; and to consider other matters.Reported Earnings • Apr 29First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: EPS: CN¥0.16 (up from CN¥0.14 in 1Q 2021). Revenue: CN¥3.46b (up 16% from 1Q 2021). Net income: CN¥427.4m (up 16% from 1Q 2021). Profit margin: 12% (in line with 1Q 2021). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Caroline Sainte-Marie was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 19Bluestar Adisseo Company, Annual General Meeting, Apr 29, 2022Bluestar Adisseo Company, Annual General Meeting, Apr 29, 2022, at 14:30 China Standard Time. Location: Meeting room in Bluestar Building, 9 Beituchengxi Road, Chaoyang District, Beijing China Agenda: To consider 2021 annual report and executive summary; to consider 2021 annual final accounts; to consider Board's report for FY 2021; to consider Board of Supervisors' report for FY 2021; and to consider other matters.Reported Earnings • Apr 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥0.55 (up from CN¥0.50 in FY 2020). Revenue: CN¥12.9b (up 8.0% from FY 2020). Net income: CN¥1.47b (up 8.9% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 18%, compared to a 48% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Mar 11Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥10.78, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 5.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥7.95 per share.Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥3.36b (up 12% from 3Q 2020). Net income: CN¥434.3m (up 15% from 3Q 2020). Profit margin: 13% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.Board Change • Nov 01Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Director Caroline Sainte-Marie was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Price Target Changed • Aug 04Price target decreased to CN¥15.11Down from CN¥16.46, the current price target is an average from 6 analysts. New target price is 38% above last closing price of CN¥10.92. Stock is down 32% over the past year.Reported Earnings • Jul 31Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.16 in 2Q 2020)The company reported a mediocre second quarter result with weaker revenues, although profit margins were flat and earnings improved. Second quarter 2021 results: Revenue: CN¥2.99b (down 1.6% from 2Q 2020). Net income: CN¥449.1m (up 5.8% from 2Q 2020). Profit margin: 15% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.Reported Earnings • May 04First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.11 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.99b (up 5.0% from 1Q 2020). Net income: CN¥367.3m (up 25% from 1Q 2020). Profit margin: 12% (up from 10% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥0.50 (vs CN¥0.37 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥11.9b (up 7.0% from FY 2019). Net income: CN¥1.35b (up 36% from FY 2019). Profit margin: 11% (up from 8.9% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.Is New 90 Day High Low • Feb 19New 90-day high: CN¥14.80The company is up 5.0% from its price of CN¥14.13 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥14.08 per share.Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥13.12, the stock is trading at a trailing P/E ratio of 27.3x, up from the previous P/E ratio of 23.6x. This compares to an average P/E of 37x in the Chemicals industry in China. Total returns to shareholders over the past three years are 16%.Is New 90 Day High Low • Jan 11New 90-day low: CN¥11.07The company is down 18% from its price of CN¥13.44 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥14.06 per share.Is New 90 Day High Low • Dec 23New 90-day low: CN¥11.88The company is down 8.0% from its price of CN¥12.92 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥14.12 per share.Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.28b, up 24% from the prior year. Total revenue was CN¥11.7b over the last 12 months, up 4.5% from the prior year.Analyst Estimate Surprise Post Earnings • Oct 30Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 3.9% at CN¥3.00b. Revenue is forecast to grow 14% over the next year, compared to a 32% growth forecast for the Chemicals industry in China.お知らせ • Oct 27Bluestar Adisseo Company to Report Q3, 2020 Results on Oct 30, 2020Bluestar Adisseo Company announced that they will report Q3, 2020 results on Oct 30, 2020Is New 90 Day High Low • Oct 22New 90-day low: CN¥12.50The company is down 4.0% from its price of CN¥13.00 on 24 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥9.91 per share.お知らせ • Sep 09Bluestar Adisseo Company (SHSE:600299) signed an agreement to acquire FraMelco B.V. from a family.Bluestar Adisseo Company (SHSE:600299) signed an agreement to acquire FraMelco B.V. from a family on September 7, 2020. FraMelco business generates gross sales of about €30 million per year.お知らせ • Jul 30Bluestar Adisseo Company (SHSE:600299) completed the acquisition remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd.Bluestar Adisseo Company (SHSE:600299) entered into an agreement to acquire remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd. for CNY 3.6 billion on January 16, 2019. The consideration will be paid in two installments with first installment of 50% of consideration within five working days from first delivery date and remaining within five working days from second delivery date. The final consideration to be paid in cash will be decided after the asset assessment results. Bluestar Adisseo Company (SHSE:600299) signed a revised equity transfer agreement to acquire remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd. for CNY 3.1 billion on October 23, 2019. Transactional price has been momentarily set in CNY 3.086 billion. Pre deal, Bluestar Adisseo Company held 85% stake and post completion, it will hold 100% stake in Blue Star Adisseo Nutrition Group Co., Ltd. Post completion, Blue Star Adisseo Nutrition Group Co., Ltd. Will operate as a subsidiary. For the year ended December 31, 2018, Blue Star Adisseo Nutrition Group Co., Ltd. has total assets of CNY 18.74 billion, operating revenue of CNY 11.42 billion and net profit of CNY 1.17 billion. The deal is subject to obtaining funding for the payment. The transaction is subject to shareholders’ approval of Bluestar Adisseo Company in meeting due on February 1, 2019. The transaction has been approved by the 3rd meeting of the 7th directorate of Bluestar Adisseo Company on January 16, 2019. The deal is disapproved by the shareholders in meeting on August 8, 2019. The deal was unanimously approved by the Board of Directors of Bluestar Adisseo Company in the eight meeting of 7th directorate on October 23, 2019. The deal has been approved by the shareholder owning preference shares of Blue Star Adisseo Nutrition Group Co., Ltd. on October 23, 2019. Bluestar Adisseo Company (SHSE:600299) completed the acquisition remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd on April 28, 2020.業績と収益の成長予測SHSE:600299 - アナリストの将来予測と過去の財務データ ( )CNY Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202821,9102,175N/A5,057312/31/202721,8072,594N/A4,847312/31/202621,9731,792N/A3,43533/31/202617,335995-4913,011N/A12/31/202517,2311,155-3723,331N/A9/30/202517,0891,191683,008N/A6/30/202516,7851,3375903,164N/A3/31/202516,3381,3921,4043,247N/A12/31/202415,5341,2041,3222,945N/A9/30/202414,9451,0901,5593,192N/A6/30/202414,1166261,3092,820N/A3/31/202413,5273281,3602,879N/A12/31/202313,184521,3172,764N/A9/30/202313,343691,2412,727N/A6/30/202313,6624111,1362,563N/A3/31/202314,2248214511,890N/A12/31/202214,5291,2471871,729N/A9/30/202214,3261,3651911,644N/A6/30/202214,0851,525121,793N/A3/31/202213,3331,5323902,424N/A12/31/202112,8691,4722882,602N/A9/30/202112,3721,504-1562,172N/A6/30/202112,0031,4493042,282N/A3/31/202112,0521,4248872,572N/A12/31/202011,9101,3521,3902,708N/A9/30/202011,7041,2791,8562,931N/A6/30/202011,6641,1781,6642,720N/A3/31/202011,2559911,7572,913N/A12/31/201911,135992N/A2,551N/A9/30/201911,2051,028N/A2,611N/A6/30/201911,025971N/A2,483N/A3/31/201911,137870N/A1,780N/A12/31/201811,418926N/A1,442N/A9/30/201811,3061,121N/A1,666N/A6/30/201811,2161,235N/A1,671N/A3/31/201810,9431,359N/A1,881N/A12/31/201710,3981,323N/A2,513N/A9/30/201710,2161,232N/A2,462N/A6/30/201710,1851,341N/A2,747N/A3/31/201710,4101,621N/A2,714N/A12/31/201610,6881,865N/A3,054N/A9/30/201611,0361,848N/A2,737N/A6/30/201611,6582,103N/A3,237N/A3/31/201613,3651,605N/A3,469N/A12/31/201515,1731,529N/A3,556N/A9/30/201517,1892,675N/A3,426N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 600299の予測収益成長率 (年間24.9% ) は 貯蓄率 ( 2.4% ) を上回っています。収益対市場: 600299の収益 ( 24.9% ) CN市場 ( 26.6% ) よりも低い成長が予測されています。高成長収益: 600299の収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: 600299の収益 ( 6.6% ) CN市場 ( 16.8% ) よりも低い成長が予測されています。高い収益成長: 600299の収益 ( 6.6% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 600299の 自己資本利益率 は、3年後には低くなると予測されています ( 9.7 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/17 12:22終値2026/08/17 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bluestar Adisseo Company 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Trina ChenGoldman SachsLin YangGuosen Securities Co., Ltd.Wei LiuHaitong International Research Limited4 その他のアナリストを表示
Major Estimate Revision • May 06Consensus revenue estimates increase by 20%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from CN¥18.5b to CN¥22.1b. EPS estimate increased from CN¥0.45 to CN¥1.09 per share. Net income forecast to grow 227% next year vs 57% growth forecast for Chemicals industry in China. Consensus price target up from CN¥12.60 to CN¥17.35. Share price fell 10% to CN¥12.80 over the past week.
Price Target Changed • Mar 06Price target increased by 8.0% to CN¥11.45Up from CN¥10.60, the current price target is an average from 2 analysts. New target price is 15% below last closing price of CN¥13.50. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.49 for next year compared to CN¥0.45 last year.
Major Estimate Revision • Jun 07Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥16.6b to CN¥16.1b. EPS estimate also fell from CN¥0.61 per share to CN¥0.48 per share. Net income forecast to shrink 1.4% next year vs 43% growth forecast for Chemicals industry in China . Consensus price target of CN¥11.45 unchanged from last update. Share price was steady at CN¥9.61 over the past week.
Major Estimate Revision • Mar 01Consensus EPS estimates increase by 16%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥16.4b to CN¥15.8b. EPS estimate rose from CN¥0.529 to CN¥0.614. Net income forecast to grow 42% next year vs 52% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥11.61. Share price fell 6.0% to CN¥10.34 over the past week.
Major Estimate Revision • Nov 22Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥15.4b to CN¥15.2b. EPS estimate also fell from CN¥0.473 per share to CN¥0.411 per share. Net income forecast to grow 14% next year vs 53% growth forecast for Chemicals industry in China. Consensus price target of CN¥11.43 unchanged from last update. Share price fell 3.2% to CN¥10.78 over the past week.
Price Target Changed • Aug 31Price target increased by 12% to CN¥11.23Up from CN¥10.01, the current price target is an average from 3 analysts. New target price is 9.9% above last closing price of CN¥10.22. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.45 for next year compared to CN¥0.019 last year.
お知らせ • Jun 30Bluestar Adisseo Company to Report First Half, 2026 Results on Aug 31, 2026Bluestar Adisseo Company announced that they will report first half, 2026 results on Aug 31, 2026
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to CN¥7.95, the stock trades at a forward P/E ratio of 8x. Average forward P/E is 21x in the Chemicals industry in China. Total returns to shareholders of 3.3% over the past three years.
Major Estimate Revision • May 06Consensus revenue estimates increase by 20%The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from CN¥18.5b to CN¥22.1b. EPS estimate increased from CN¥0.45 to CN¥1.09 per share. Net income forecast to grow 227% next year vs 57% growth forecast for Chemicals industry in China. Consensus price target up from CN¥12.60 to CN¥17.35. Share price fell 10% to CN¥12.80 over the past week.
Reported Earnings • May 01First quarter 2026 earnings released: EPS: CN¥0.10 (vs CN¥0.17 in 1Q 2025)First quarter 2026 results: EPS: CN¥0.10 (down from CN¥0.17 in 1Q 2025). Revenue: CN¥4.40b (up 2.4% from 1Q 2025). Net income: CN¥305.5m (down 34% from 1Q 2025). Profit margin: 6.9% (down from 11% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
お知らせ • Apr 30Bluestar Adisseo Company, Annual General Meeting, May 22, 2026Bluestar Adisseo Company, Annual General Meeting, May 22, 2026, at 14:00 China Standard Time. Location: No. 9, Beitucheng West Road, Chaoyang District, Beijing China
New Risk • Apr 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (8.3% average weekly change).
お知らせ • Mar 30Bluestar Adisseo Company to Report Q1, 2026 Results on Apr 30, 2026Bluestar Adisseo Company announced that they will report Q1, 2026 results on Apr 30, 2026
Reported Earnings • Mar 10Full year 2025 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2025 results: EPS: CN¥0.43 (down from CN¥0.45 in FY 2024). Revenue: CN¥17.2b (up 11% from FY 2024). Net income: CN¥1.15b (down 4.1% from FY 2024). Profit margin: 6.7% (down from 7.8% in FY 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.9%. Earnings per share (EPS) missed analyst estimates by 12%. Revenue is forecast to grow 4.0% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
Price Target Changed • Mar 06Price target increased by 8.0% to CN¥11.45Up from CN¥10.60, the current price target is an average from 2 analysts. New target price is 15% below last closing price of CN¥13.50. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.49 for next year compared to CN¥0.45 last year.
Valuation Update With 7 Day Price Move • Mar 02Investor sentiment improves as stock rises 15%After last week's 15% share price gain to CN¥11.66, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 28x in the Chemicals industry in China. Total returns to shareholders of 35% over the past three years.
Upcoming Dividend • Feb 20Upcoming dividend of CN¥0.051 per shareEligible shareholders must have bought the stock before 27 February 2026. Payment date: 27 February 2026. Payout ratio is a comfortable 38% but the company is paying out more than the cash it is generating. Trailing yield: 1.7%. Lower than top quartile of Chinese dividend payers (1.8%). Higher than average of industry peers (1.2%).
お知らせ • Dec 26Bluestar Adisseo Company to Report Fiscal Year 2025 Results on Mar 07, 2026Bluestar Adisseo Company announced that they will report fiscal year 2025 results on Mar 07, 2026
Reported Earnings • Oct 31Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2025 results: EPS: CN¥0.094 (down from CN¥0.14 in 3Q 2024). Revenue: CN¥4.42b (up 7.4% from 3Q 2024). Net income: CN¥250.2m (down 37% from 3Q 2024). Profit margin: 5.7% (down from 9.6% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 45%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Sep 30Bluestar Adisseo Company to Report Q3, 2025 Results on Oct 31, 2025Bluestar Adisseo Company announced that they will report Q3, 2025 results on Oct 31, 2025
Reported Earnings • Sep 04Second quarter 2025 earnings: EPS and revenues miss analyst expectationsSecond quarter 2025 results: EPS: CN¥0.11 (down from CN¥0.13 in 2Q 2024). Revenue: CN¥4.21b (up 12% from 2Q 2024). Net income: CN¥275.4m (down 17% from 2Q 2024). Profit margin: 6.5% (down from 8.8% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) also missed analyst estimates by 22%. Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • Jun 30Bluestar Adisseo Company to Report First Half, 2025 Results on Aug 30, 2025Bluestar Adisseo Company announced that they will report first half, 2025 results on Aug 30, 2025
Major Estimate Revision • Jun 07Consensus EPS estimates fall by 21%The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from CN¥16.6b to CN¥16.1b. EPS estimate also fell from CN¥0.61 per share to CN¥0.48 per share. Net income forecast to shrink 1.4% next year vs 43% growth forecast for Chemicals industry in China . Consensus price target of CN¥11.45 unchanged from last update. Share price was steady at CN¥9.61 over the past week.
Reported Earnings • May 01First quarter 2025 earnings released: EPS: CN¥0.17 (vs CN¥0.10 in 1Q 2024)First quarter 2025 results: EPS: CN¥0.17 (up from CN¥0.10 in 1Q 2024). Revenue: CN¥4.30b (up 23% from 1Q 2024). Net income: CN¥464.8m (up 68% from 1Q 2024). Profit margin: 11% (up from 7.9% in 1Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings.
お知らせ • Mar 28Bluestar Adisseo Company to Report Q1, 2025 Results on Apr 29, 2025Bluestar Adisseo Company announced that they will report Q1, 2025 results on Apr 29, 2025
Major Estimate Revision • Mar 01Consensus EPS estimates increase by 16%, revenue downgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from CN¥16.4b to CN¥15.8b. EPS estimate rose from CN¥0.529 to CN¥0.614. Net income forecast to grow 42% next year vs 52% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥11.61. Share price fell 6.0% to CN¥10.34 over the past week.
お知らせ • Feb 28Bluestar Adisseo Company, Annual General Meeting, Mar 24, 2025Bluestar Adisseo Company, Annual General Meeting, Mar 24, 2025, at 14:00 China Standard Time. Location: No. 9, Beitucheng West Road, Chaoyang District, Beijing China
分析記事 • Feb 06We Think Bluestar Adisseo (SHSE:600299) Can Manage Its Debt With EaseLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Jan 12Estimating The Fair Value Of Bluestar Adisseo Company (SHSE:600299)Key Insights Bluestar Adisseo's estimated fair value is CN¥12.50 based on 2 Stage Free Cash Flow to Equity Bluestar...
お知らせ • Dec 27Bluestar Adisseo Company to Report Fiscal Year 2024 Results on Feb 28, 2025Bluestar Adisseo Company announced that they will report fiscal year 2024 results on Feb 28, 2025
分析記事 • Dec 25Returns At Bluestar Adisseo (SHSE:600299) Appear To Be Weighed DownIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
分析記事 • Dec 06Investor Optimism Abounds Bluestar Adisseo Company (SHSE:600299) But Growth Is LackingWith a median price-to-sales (or "P/S") ratio of close to 2.4x in the Chemicals industry in China, you could be...
Major Estimate Revision • Nov 22Consensus EPS estimates fall by 13%The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥15.4b to CN¥15.2b. EPS estimate also fell from CN¥0.473 per share to CN¥0.411 per share. Net income forecast to grow 14% next year vs 53% growth forecast for Chemicals industry in China. Consensus price target of CN¥11.43 unchanged from last update. Share price fell 3.2% to CN¥10.78 over the past week.
Reported Earnings • Oct 30Third quarter 2024 earnings: EPS and revenues exceed analyst expectationsThird quarter 2024 results: EPS: CN¥0.14 (up from CN¥0.014 loss in 3Q 2023). Revenue: CN¥4.11b (up 25% from 3Q 2023). Net income: CN¥395.7m (up CN¥463.5m from 3Q 2023). Profit margin: 9.6% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 5.5%. Earnings per share (EPS) also surpassed analyst estimates by 4.0%. Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
分析記事 • Oct 11We Think Bluestar Adisseo (SHSE:600299) Can Manage Its Debt With EaseDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
お知らせ • Sep 30Bluestar Adisseo Company to Report Q3, 2024 Results on Oct 30, 2024Bluestar Adisseo Company announced that they will report Q3, 2024 results on Oct 30, 2024
Valuation Update With 7 Day Price Move • Sep 30Investor sentiment improves as stock rises 16%After last week's 16% share price gain to CN¥11.29, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 16x in the Chemicals industry in China. Total loss to shareholders of 1.0% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥12.84 per share.
分析記事 • Sep 23Bluestar Adisseo (SHSE:600299) Is Finding It Tricky To Allocate Its CapitalWhat financial metrics can indicate to us that a company is maturing or even in decline? Businesses in decline often...
Reported Earnings • Sep 04Second quarter 2024 earnings: EPS in line with expectations, revenues disappointSecond quarter 2024 results: EPS: CN¥0.13 (up from CN¥0.011 in 2Q 2023). Revenue: CN¥3.77b (up 19% from 2Q 2023). Net income: CN¥330.7m (up CN¥298.8m from 2Q 2023). Profit margin: 8.8% (up from 1.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 55% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
分析記事 • Sep 04Getting In Cheap On Bluestar Adisseo Company (SHSE:600299) Is UnlikelyThere wouldn't be many who think Bluestar Adisseo Company's ( SHSE:600299 ) price-to-sales (or "P/S") ratio of 2x is...
Price Target Changed • Aug 31Price target increased by 12% to CN¥11.23Up from CN¥10.01, the current price target is an average from 3 analysts. New target price is 9.9% above last closing price of CN¥10.22. Stock is up 26% over the past year. The company is forecast to post earnings per share of CN¥0.45 for next year compared to CN¥0.019 last year.
お知らせ • Jun 28Bluestar Adisseo Company to Report First Half, 2024 Results on Aug 30, 2024Bluestar Adisseo Company announced that they will report first half, 2024 results on Aug 30, 2024
分析記事 • Jun 21Are Investors Undervaluing Bluestar Adisseo Company (SHSE:600299) By 32%?Key Insights Bluestar Adisseo's estimated fair value is CN¥14.20 based on 2 Stage Free Cash Flow to Equity Bluestar...
お知らせ • Jun 08Bluestar Adisseo Company, Annual General Meeting, Jun 26, 2024Bluestar Adisseo Company, Annual General Meeting, Jun 26, 2024, at 14:00 China Standard Time. Location: No. 9, Beitucheng West Road, Chaoyang District, Beijing China
Reported Earnings • Apr 27First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFirst quarter 2024 results: EPS: CN¥0.10 (up from CN¥0.001 in 1Q 2023). Revenue: CN¥3.50b (up 11% from 1Q 2023). Net income: CN¥276.9m (up CN¥275.4m from 1Q 2023). Profit margin: 7.9% (up from 0% in 1Q 2023). Revenue missed analyst estimates by 1.2%. Earnings per share (EPS) exceeded analyst estimates by 35%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Apr 27Bluestar Adisseo Company announced that it expects to receive CNY 3 billion in fundingBluestar Adisseo Company announced a private placement of not more than 804,570,381 shares for the gross proceeds of not more than CNY 3,000,000,000 on April 25, 2024. The company shall issue shares at a price not less than 80% of the average price in the 20 trading days before the pricing reference date. The transaction will include participation from no more than 35 investors. The transaction has been approved by the shareholders of the company in the 18th meeting of the 8th board of directors and the 12th meeting of the 8th board of supervisors. The transaction is subject to to review and approval by the listed company’s general meeting of shareholders; by the Shanghai Stock Exchange and approval by the China Securities Regulatory Commission for registration.
分析記事 • Apr 25Bluestar Adisseo's (SHSE:600299) Returns On Capital Not Reflecting Well On The BusinessWhen we're researching a company, it's sometimes hard to find the warning signs, but there are some financial metrics...
分析記事 • Apr 04There May Be Some Bright Spots In Bluestar Adisseo's (SHSE:600299) EarningsBluestar Adisseo Company's ( SHSE:600299 ) recent soft profit numbers didn't appear to worry shareholders, as the stock...
Reported Earnings • Mar 31Full year 2023 earnings: EPS and revenues miss analyst expectationsFull year 2023 results: EPS: CN¥0.02 (down from CN¥0.47 in FY 2022). Revenue: CN¥13.2b (down 9.3% from FY 2022). Net income: CN¥52.2m (down 96% from FY 2022). Profit margin: 0.4% (down from 8.6% in FY 2022). Revenue missed analyst estimates by 7.8%. Earnings per share (EPS) also missed analyst estimates by 68%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 14% per year, which means it has not declined as severely as earnings.
お知らせ • Mar 29Bluestar Adisseo Company to Report Q1, 2024 Results on Apr 26, 2024Bluestar Adisseo Company announced that they will report Q1, 2024 results on Apr 26, 2024
分析記事 • Mar 27Is Bluestar Adisseo (SHSE:600299) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Major Estimate Revision • Mar 08Consensus EPS estimates increase by 21%The consensus outlook for fiscal year 2023 has been updated. 2023 EPS estimate increased from CN¥0.069 to CN¥0.084. Revenue forecast steady at CN¥14.3b. Net income forecast to grow 959% next year vs 59% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥9.88. Share price fell 2.1% to CN¥8.46 over the past week.
分析記事 • Mar 06Optimistic Investors Push Bluestar Adisseo Company (SHSE:600299) Shares Up 25% But Growth Is LackingBluestar Adisseo Company ( SHSE:600299 ) shareholders would be excited to see that the share price has had a great...
分析記事 • Feb 28Is There An Opportunity With Bluestar Adisseo Company's (SHSE:600299) 32% Undervaluation?Key Insights Using the 2 Stage Free Cash Flow to Equity, Bluestar Adisseo fair value estimate is CN¥12.56 Current share...
お知らせ • Dec 29Bluestar Adisseo Company to Report Fiscal Year 2023 Results on Mar 29, 2024Bluestar Adisseo Company announced that they will report fiscal year 2023 results on Mar 29, 2024
Major Estimate Revision • Nov 14Consensus EPS estimates increase by 10%, revenue downgradedThe consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CN¥15.0b to CN¥14.7b. EPS estimate rose from CN¥0.134 to CN¥0.147. Net income forecast to grow 1,037% next year vs 70% growth forecast for Chemicals industry in China. Consensus price target broadly unchanged at CN¥9.81. Share price was steady at CN¥7.76 over the past week.
Reported Earnings • Nov 01Third quarter 2023 earnings: EPS and revenues miss analyst expectationsThird quarter 2023 results: CN¥0.014 loss per share (down from CN¥0.10 profit in 3Q 2022). Revenue: CN¥3.29b (down 8.8% from 3Q 2022). Net loss: CN¥67.8m (down 125% from profit in 3Q 2022). Revenue missed analyst estimates by 2.8%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings.
New Risk • Aug 06New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (111% payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.0% net profit margin).
Reported Earnings • Aug 05Second quarter 2023 earnings: EPS and revenues miss analyst expectationsSecond quarter 2023 results: EPS: CN¥0.008 (down from CN¥0.16 in 2Q 2022). Revenue: CN¥3.18b (down 15% from 2Q 2022). Net income: CN¥31.9m (down 93% from 2Q 2022). Profit margin: 1.0% (down from 12% in 2Q 2022). Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 94%. Revenue is forecast to grow 9.6% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 28Bluestar Adisseo Company to Report First Half, 2023 Results on Aug 05, 2023Bluestar Adisseo Company announced that they will report first half, 2023 results on Aug 05, 2023
Major Estimate Revision • Jun 01Consensus revenue estimates decrease by 17%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from CN¥15.3b to CN¥12.8b. EPS estimate unchanged from CN¥0.58 per share at last update. Chemicals industry in China expected to see average net income growth of 47% next year. Consensus price target down from CN¥11.84 to CN¥10.42. Share price was steady at CN¥7.96 over the past week.
Reported Earnings • Apr 28First quarter 2023 earnings: EPS and revenues miss analyst expectationsFirst quarter 2023 results: EPS: CN¥0.001 (down from CN¥0.16 in 1Q 2022). Revenue: CN¥3.15b (down 8.8% from 1Q 2022). Net income: CN¥1.49m (down 100% from 1Q 2022). Profit margin: 0% (down from 12% in 1Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 8.7%. Earnings per share (EPS) also missed analyst estimates by 100%. Revenue is forecast to grow 8.9% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Price Target Changed • Apr 06Price target decreased by 7.6% to CN¥11.84Down from CN¥12.81, the current price target is an average from 4 analysts. New target price is 27% above last closing price of CN¥9.29. Stock is down 4.0% over the past year. The company is forecast to post earnings per share of CN¥0.55 for next year compared to CN¥0.55 last year.
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Caroline Sainte-Marie was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Major Estimate Revision • Nov 03Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from CN¥0.61 to CN¥0.54. Revenue forecast unchanged from CN¥14.8b at last update. Net income forecast to grow 43% next year vs 44% growth forecast for Chemicals industry in China. Consensus price target of CN¥12.76 unchanged from last update. Share price fell 8.9% to CN¥8.73 over the past week.
Reported Earnings • Oct 28Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behindThird quarter 2022 results: EPS: CN¥0.10 (down from CN¥0.17 in 3Q 2021). Revenue: CN¥3.60b (up 7.2% from 3Q 2021). Net income: CN¥274.2m (down 37% from 3Q 2021). Profit margin: 7.6% (down from 13% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 6.0%. Earnings per share (EPS) missed analyst estimates by 28%. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Chemicals industry in China. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥10.76, the stock trades at a forward P/E ratio of 16x. Average forward P/E is 17x in the Chemicals industry in China. Total returns to shareholders of 11% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥5.70 per share.
Price Target Changed • Aug 18Price target decreased to CN¥12.76Down from CN¥14.22, the current price target is an average from 5 analysts. New target price is 35% above last closing price of CN¥9.46. Stock is down 13% over the past year. The company is forecast to post earnings per share of CN¥0.57 for next year compared to CN¥0.55 last year.
Major Estimate Revision • Aug 04Consensus EPS estimates fall by 22%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from CN¥15.3b to CN¥14.2b. EPS estimate also fell from CN¥0.73 per share to CN¥0.57 per share. Net income forecast to grow 33% next year vs 41% growth forecast for Chemicals industry in China. Consensus price target down from CN¥14.53 to CN¥14.13. Share price fell 5.6% to CN¥9.18 over the past week.
Reported Earnings • Jul 30Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.16 in 2Q 2021)Second quarter 2022 results: EPS: CN¥0.16 (down from CN¥0.16 in 2Q 2021). Revenue: CN¥3.74b (up 25% from 2Q 2021). Net income: CN¥442.1m (down 1.6% from 2Q 2021). Profit margin: 12% (down from 15% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 6.5%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Price Target Changed • Jun 24Price target decreased to CN¥13.40Down from CN¥15.11, the current price target is an average from 3 analysts. New target price is 38% above last closing price of CN¥9.70. Stock is down 22% over the past year. The company is forecast to post earnings per share of CN¥0.72 for next year compared to CN¥0.55 last year.
お知らせ • May 07Bluestar Adisseo Company, Annual General Meeting, May 16, 2022Bluestar Adisseo Company, Annual General Meeting, May 16, 2022, at 14:30 China Standard Time. Location: Bluestar Building, 9 Beituchengxi Road, Chaoyang District, Beijing Bejing China Agenda: To consider 2022 annual report and executive summary; to consider 2022 annual final accounts; to consider Board's report for FY 2022; to consider Board of Supervisors' report for FY 2022; and to consider other matters.
Reported Earnings • Apr 29First quarter 2022 earnings: EPS in line with expectations, revenues disappointFirst quarter 2022 results: EPS: CN¥0.16 (up from CN¥0.14 in 1Q 2021). Revenue: CN¥3.46b (up 16% from 1Q 2021). Net income: CN¥427.4m (up 16% from 1Q 2021). Profit margin: 12% (in line with 1Q 2021). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 11%, compared to a 42% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Caroline Sainte-Marie was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 19Bluestar Adisseo Company, Annual General Meeting, Apr 29, 2022Bluestar Adisseo Company, Annual General Meeting, Apr 29, 2022, at 14:30 China Standard Time. Location: Meeting room in Bluestar Building, 9 Beituchengxi Road, Chaoyang District, Beijing China Agenda: To consider 2021 annual report and executive summary; to consider 2021 annual final accounts; to consider Board's report for FY 2021; to consider Board of Supervisors' report for FY 2021; and to consider other matters.
Reported Earnings • Apr 03Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: CN¥0.55 (up from CN¥0.50 in FY 2020). Revenue: CN¥12.9b (up 8.0% from FY 2020). Net income: CN¥1.47b (up 8.9% from FY 2020). Profit margin: 11% (in line with FY 2020). Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) were mostly in line with analyst estimates. Over the next year, revenue is forecast to grow 18%, compared to a 48% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Mar 11Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to CN¥10.78, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Chemicals industry in China. Total loss to shareholders of 5.3% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥7.95 per share.
Reported Earnings • Nov 01Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 3Q 2020)The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥3.36b (up 12% from 3Q 2020). Net income: CN¥434.3m (up 15% from 3Q 2020). Profit margin: 13% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
Board Change • Nov 01Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Director Caroline Sainte-Marie was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Price Target Changed • Aug 04Price target decreased to CN¥15.11Down from CN¥16.46, the current price target is an average from 6 analysts. New target price is 38% above last closing price of CN¥10.92. Stock is down 32% over the past year.
Reported Earnings • Jul 31Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.16 in 2Q 2020)The company reported a mediocre second quarter result with weaker revenues, although profit margins were flat and earnings improved. Second quarter 2021 results: Revenue: CN¥2.99b (down 1.6% from 2Q 2020). Net income: CN¥449.1m (up 5.8% from 2Q 2020). Profit margin: 15% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings.
Reported Earnings • May 04First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.11 in 1Q 2020)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥2.99b (up 5.0% from 1Q 2020). Net income: CN¥367.3m (up 25% from 1Q 2020). Profit margin: 12% (up from 10% in 1Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 01Full year 2020 earnings released: EPS CN¥0.50 (vs CN¥0.37 in FY 2019)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥11.9b (up 7.0% from FY 2019). Net income: CN¥1.35b (up 36% from FY 2019). Profit margin: 11% (up from 8.9% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 1% per year.
Is New 90 Day High Low • Feb 19New 90-day high: CN¥14.80The company is up 5.0% from its price of CN¥14.13 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 20% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥14.08 per share.
Valuation Update With 7 Day Price Move • Jan 21Investor sentiment improved over the past weekAfter last week's 15% share price gain to CN¥13.12, the stock is trading at a trailing P/E ratio of 27.3x, up from the previous P/E ratio of 23.6x. This compares to an average P/E of 37x in the Chemicals industry in China. Total returns to shareholders over the past three years are 16%.
Is New 90 Day High Low • Jan 11New 90-day low: CN¥11.07The company is down 18% from its price of CN¥13.44 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥14.06 per share.
Is New 90 Day High Low • Dec 23New 90-day low: CN¥11.88The company is down 8.0% from its price of CN¥12.92 on 24 September 2020. The Chinese market is up 2.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥14.12 per share.
Reported Earnings • Oct 30Third quarter earnings releasedOver the last 12 months the company has reported total profits of CN¥1.28b, up 24% from the prior year. Total revenue was CN¥11.7b over the last 12 months, up 4.5% from the prior year.
Analyst Estimate Surprise Post Earnings • Oct 30Third-quarter earnings released: Revenue misses expectationsThird-quarter revenue missed analyst estimates by 3.9% at CN¥3.00b. Revenue is forecast to grow 14% over the next year, compared to a 32% growth forecast for the Chemicals industry in China.
お知らせ • Oct 27Bluestar Adisseo Company to Report Q3, 2020 Results on Oct 30, 2020Bluestar Adisseo Company announced that they will report Q3, 2020 results on Oct 30, 2020
Is New 90 Day High Low • Oct 22New 90-day low: CN¥12.50The company is down 4.0% from its price of CN¥13.00 on 24 July 2020. The Chinese market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 4.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is CN¥9.91 per share.
お知らせ • Sep 09Bluestar Adisseo Company (SHSE:600299) signed an agreement to acquire FraMelco B.V. from a family.Bluestar Adisseo Company (SHSE:600299) signed an agreement to acquire FraMelco B.V. from a family on September 7, 2020. FraMelco business generates gross sales of about €30 million per year.
お知らせ • Jul 30Bluestar Adisseo Company (SHSE:600299) completed the acquisition remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd.Bluestar Adisseo Company (SHSE:600299) entered into an agreement to acquire remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd. for CNY 3.6 billion on January 16, 2019. The consideration will be paid in two installments with first installment of 50% of consideration within five working days from first delivery date and remaining within five working days from second delivery date. The final consideration to be paid in cash will be decided after the asset assessment results. Bluestar Adisseo Company (SHSE:600299) signed a revised equity transfer agreement to acquire remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd. for CNY 3.1 billion on October 23, 2019. Transactional price has been momentarily set in CNY 3.086 billion. Pre deal, Bluestar Adisseo Company held 85% stake and post completion, it will hold 100% stake in Blue Star Adisseo Nutrition Group Co., Ltd. Post completion, Blue Star Adisseo Nutrition Group Co., Ltd. Will operate as a subsidiary. For the year ended December 31, 2018, Blue Star Adisseo Nutrition Group Co., Ltd. has total assets of CNY 18.74 billion, operating revenue of CNY 11.42 billion and net profit of CNY 1.17 billion. The deal is subject to obtaining funding for the payment. The transaction is subject to shareholders’ approval of Bluestar Adisseo Company in meeting due on February 1, 2019. The transaction has been approved by the 3rd meeting of the 7th directorate of Bluestar Adisseo Company on January 16, 2019. The deal is disapproved by the shareholders in meeting on August 8, 2019. The deal was unanimously approved by the Board of Directors of Bluestar Adisseo Company in the eight meeting of 7th directorate on October 23, 2019. The deal has been approved by the shareholder owning preference shares of Blue Star Adisseo Nutrition Group Co., Ltd. on October 23, 2019. Bluestar Adisseo Company (SHSE:600299) completed the acquisition remaining 15% stake in Blue Star Adisseo Nutrition Group Co., Ltd. from China National BlueStar (Group) Co., Ltd on April 28, 2020.